CH \$240.00 90488

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 ETAS ID: TM801055

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	TRADEMARK SECURITY AGREEMENT

CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
IMMUNOGEN, INC.		04/06/2023	Corporation: MASSACHUSETTS

RECEIVING PARTY DATA

Name:	BIOPHARMA CREDIT PLC
Street Address:	C/O BEAUFORT HOUSE, 51 NEW NORTH ROAD
City:	EXETER EX4 4EP
State/Country:	UNITED KINGDOM
Entity Type:	Private Limited Company: ENGLAND AND WALES

PROPERTY NUMBERS Total: 9

Property Type	Number	Word Mark
Serial Number:	90488884	ELAHERE
Serial Number:	97693875	ELAHERE
Serial Number:	97676668	
Serial Number:	97532782	FR-ASSIST
Serial Number:	97676672	ELAHERE
Serial Number:	97532787	FR-ASSIST
Serial Number:	97693877	ELAHERE SUPPORT SERVICES
Serial Number:	97693878	ELAHERE SUPPORT SERVICES
Serial Number:	97693879	ELAHERE MIRVETUXIMAB SORAVTANSINE INJECT

CORRESPONDENCE DATA

Fax Number: 2028874288

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 2028874000

Email: mbeyene@akingump.com, DC_IPDocketing@AKINGUMP.com

Correspondent Name: Mussie B Beyene Address Line 1: 2001 K Street N.W.

Address Line 4: Washington DC, D.C. 20006

ATTORNEY DOCKET NUMBER:	687747.0070
NAME OF SUBMITTER:	Mussie B Beyene

SIGNATURE:	/Mussie B Beyene/
DATE SIGNED:	04/06/2023
Total Attachments: 7	
source=Active_134174356_5_Immuno@	Gen - Trademark Security Agreement - Executed#page1.tif
source=Active_134174356_5_lmmuno@	Gen - Trademark Security Agreement - Executed#page2.tif
source=Active_134174356_5_lmmuno@	Gen - Trademark Security Agreement - Executed#page3.tif
source=Active_134174356_5_Immuno0	Gen - Trademark Security Agreement - Executed#page4.tif
source=Active_134174356_5_lmmuno@	Gen - Trademark Security Agreement - Executed#page5.tif
source=Active_134174356_5_lmmuno@	Gen - Trademark Security Agreement - Executed#page6.tif
source=Active_134174356_5_lmmuno0	Gen - Trademark Security Agreement - Executed#page7.tif

TRADEMARK SECURITY AGREEMENT

THIS TRADEMARK SECURITY AGREEMENT, dated as of April 6, 2023, is made by IMMUNOGEN, INC. ("Grantor"), in favor of BIOPHARMA CREDIT PLC (together with its successors and permitted assigns, the "Collateral Agent") on behalf of Lenders and the other Secured Parties (as defined in the Loan Agreement referred to below).

WITNESSETH:

WHEREAS, pursuant to the Loan Agreement, dated as of April 6, 2023 (as the same may be amended, amended and restated, supplemented or otherwise modified from time to time, the "Loan Agreement"), by and among IMMUNOGEN, INC., a Massachusetts corporation ("Borrower"), the other parties thereto from time to time, as additional Credit Parties, BIOPHARMA CREDIT PLC, as Collateral Agent, BPCR LIMITED PARTNERSHIP, (as a "Lender") and BIOPHARMA CREDIT INVESTMENTS V (MASTER) LP, a Cayman Islands exempted limited partnership acting by its general partner, BioPharma Credit Investments V GP LLC (as a "Lender"), each Lender has agreed to make extensions of credit to Borrower upon the terms and subject to the conditions set forth therein;

WHEREAS, Grantor has agreed, pursuant to a Guaranty and Security Agreement dated as of April 6, 2023 in favor of the Collateral Agent for the benefit of Lenders and the other Secured Parties (as such agreement may be amended, amended and restated, supplemented or otherwise modified from time to time, the "Guaranty and Security Agreement"), to guarantee the Obligations (as defined in the Loan Agreement) of Borrower; and

WHEREAS, Grantor is party to the Guaranty and Security Agreement pursuant to which Grantor is required to execute and deliver this Trademark Security Agreement;

NOW, THEREFORE, in consideration of the mutual covenants, terms and conditions set forth herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree, intending to be legally bound, as follows:

- Section 1. <u>Defined Terms.</u> Capitalized terms used herein without definition are used as defined in the Guaranty and Security Agreement.
- Section 2. <u>Grant of Security Interest in Trademark Collateral.</u> Grantor, as collateral security for the prompt and complete payment and performance when due (whether at stated maturity, by acceleration or otherwise) of the Secured Obligations, hereby mortgages, pledges and hypothecates to the Collateral Agent, for the benefit of Lenders and the other Secured Parties, and grants to the Collateral Agent, for the benefit of Lenders and the other Secured Parties, a Lien on and security interest in, all of its right, title and interest in, to and under the following Collateral of Grantor, in each case, solely to the extent constituting Collateral (and excluding any Excluded Property) (the "Trademark Collateral"):
- (a) all of its Trademarks, including, without limitation, those referred to on <u>Schedule 1</u> hereto, but excluding any "intent-to-use" application for registration of a United States Trademark for which a "Statement of Use" pursuant to Section 1(d) of the Lanham Act, 15 U.S.C. § 1051 (or any successor provision) or an "Amendment to Allege Use" pursuant to Section 1(c) of the Lanham Act, 15 U.S.C. § 1051 (or any successor provision) has not been filed with and accepted by the Applicable IP Office (but only excluding such intent-to-use application until such statement of use or amendment to allege use (as applicable) is filed with and accepted by the Applicable IP Office);
 - (b) all renewals and extensions of the foregoing;
- (c) all goodwill of the business connected with the use of, and symbolized by, each such Trademark; and

- (d) all income, royalties, proceeds and liabilities at any time due or payable or asserted under and with respect to any of the foregoing, including, without limitation, all rights to sue and recover at law or in equity for any past, present and future infringement, misappropriation, dilution, violation or other impairment thereof.
- Section 3. <u>Guaranty and Security Agreement</u>. The security interest granted pursuant to this Trademark Security Agreement is granted in conjunction with the security interest granted to the Collateral Agent for the benefit of Lenders and the other Secured Parties, pursuant to the Guaranty and Security Agreement and Grantor hereby acknowledges and agrees that the obligations, rights and remedies of Grantor and of the Collateral Agent on behalf of Lenders and the other Secured Parties with respect to the security interest in the Trademark Collateral made and granted hereby are more fully set forth in the Guaranty and Security Agreement, the terms and provisions of which are incorporated by reference herein as if fully set forth herein.
- Section 4. <u>Grantor Remains Liable.</u> Grantor hereby agrees that, anything herein to the contrary notwithstanding, Grantor shall assume full and complete responsibility for the prosecution, defense, enforcement or any other reasonably necessary actions in connection with their Trademarks subject to a security interest hereunder.
- Section 5. <u>Counterparts.</u> This Trademark Security Agreement may be executed in any number of counterparts and by different parties in separate counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement. Signature pages may be detached from multiple separate counterparts and attached to a single counterpart. Delivery of an executed signature page of this Trademark Security Agreement by facsimile transmission or electronic transmission shall be as effective as delivery of a manually executed counterpart hereof.
- Section 6. Governing Law. THIS TRADEMARK SECURITY AGREEMENT AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES HERETO SHALL BE GOVERNED BY, AND CONSTRUED AND INTERPRETED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK, WITHOUT REGARD TO ANY PRINCIPLES OF CONFLICTS OF LAW THAT COULD REQUIRE THE APPLICATION OF THE LAW OF ANY OTHER JURISDICTION, PROVIDED, HOWEVER, THAT IF THE LAWS OF ANY JURISDICTION OTHER THAN NEW YORK SHALL GOVERN IN REGARD TO THE VALIDITY, PERFECTION OR EFFECT OF PERFECTION OF ANY LIEN OR IN REGARD TO PROCEDURAL MATTERS AFFECTING ENFORCEMENT OF ANY LIENS IN TRADEMARK COLLATERAL, SUCH LAWS OF SUCH OTHER JURISDICTIONS SHALL APPLY TO THAT EXTENT.

THE TERMS OF SECTION 10 OF THE LOAN AGREEMENT ARE INCORPORATED HEREIN BY REFERENCE, *MUTATIS MUTANDIS*, AS IF SET FORTH IN FULL HEREIN AND THE PARTIES HERETO AGREE TO SUCH TERMS AND TO BE BOUND BY SUCH TERMS.

Section 7. <u>Termination</u>. Upon the absolute, unconditional and irrevocable payment in full of the Secured Obligations (other than contingent indemnification obligations to the extent no claim giving rise thereto has been asserted) in accordance with the provisions of the Loan Agreement and the expiration or termination of the Term Loan Commitments, the security interest in the Trademark Collateral granted hereby shall automatically terminate, without delivery of any instrument or performance of any act by any party, and all rights to the Trademark Collateral shall automatically revert to Grantors or any other Person entitled thereto. At such time, the Collateral Agent authorizes the filing by such Grantor of an appropriate termination hereof.

IN WITNESS WHEREOF, Grantor has caused this Trademark Security Agreement to be executed and delivered by its duly authorized officer as of the date first set forth above.

Very truly yours,

IMMUNOGEN, INC.

as Grantor

Name: Daniel Char Title: Secretary ACCEPTED AND AGREED as of the date first above written:

BIOPHARMA CREDIT PLC, as Collateral Agent

By: Pharmakon Advisors, LP, its Investment Manager

By: Pharmakon Management I, LLC, its General Partner

Name Pedro Gonzalez de Cosio

Title: Managing Member

SCHEDULE I TO TRADEMARK SECURITY AGREEMENT

Trademark Registrations and Applications

(See Attached)

134174356_3

TRADEMARK PORTFOLIO

ImmunoGen, Inc. April 4, 2023 CONFIDENTIAL IK	1032	1032	T031	T031	T031	050L	7030	1030	1029	1029	T029	1028	T028	1028	T026	ТО26	T026	7015	T015	1015	7015	7015	T015	1015	1015	
NFORMATION - N																										
immunogen, inc. April 4, 2023 CONFIDENTIAL INFORMATION - NOT FOR FURTHER DISTRIBUTION	ଞ	EM	SO	GB	E/M	SS	GB	EM	US	GB	ΕM	US	GB	EM	Sn	GB	EM	S	Sn	SC	ÜS	68	GB	EW	EM	
STRIBUTION																										
	001	001	001	001	001	001	001	001	001	001	001	001	001	001	001	001	001	003	003	002	001	002	001	002	100	
	MPR	MPR	làd	MPR	MPR	. PR:	MPK	MPR	Wes	MPR	MPR	PRI	MPR	MPR	MPR	MPR	MPS	ORD	ORD	ORD	ER.	PRI	MPR	SdW	MPR	
	ELAHERE SUPPORT SERVICES (& Starburst Logo)	ELAHERE SUPPORT SERVICES (& Starburst Logo)	ELAHERE SUPPORT SERVICES	ELAHERE SUPPORT SERVICES	ELAHERE SUPPORT SERVICES	FR-(ALPHA)SSIST	FR-(ALPHA)SSIST	FR-(ALPHA)SSIST	ELAHERE & DESIGN	ELAHERE & DESIGN	ELAMERE & DESIGN	FR-ASSIST	FR-ASSIST	FR-ASSIST	MIRVETUXIMAB STARBURST LOGO	MIRVETUXIMAB STARBURST LOGO	MIRVETUXIMAB STARBURST LOGO	ELAHERE	ELAHERE	ELAHERE	ELAHERE	ELAHERE	ELAHERE	ELAHERE	ELAHERE	
	1.MK-SHELL	TIBHS-\$M\$	Pending	TWK-SHELL	TWK-SHELL	Pending	Pending	Pending	Pending	Pending	Pending	Pending	Pending	Pending	Pending	Pending	Published	Pending	Allowed	Abandoned	Abandoned	TMK-SHELL	Registered	TMK-SHELL	Registered	
			97693877			97532787	A0131849	A0131849	97676672	1705317	1705317	97532782	A0131848	A0131848	97676668	1705316	1705316	97693875	90/488,884	90/009,729	88/268,164		1479993		1479993	
			Nov 28, 2022			3-Aug-2022	Jan 25, 2023	Jan 25, 2023	Nov 14, 2022	Nov 18, 2022	Nov 18, 2022	3-Aug-2022	Jan 25, 2023	Jan 25, 2023	Nov 14, 2022	Nov 18, 2022	Nov 18, 2022	28-Nov-2022	26-Jan-2021	18-Jun-2020	18-Jan-2019		28-Jun-2019		610Z-unr-8Z	
																							1479993		1479993	
																							12-Nov-2019		7-Jan-2020	

TRADEMARK PORTFOLIO

			2		NOI	ImmunoGen, Inc. April 4, 2023 CONFIDENTIAL INFORMATION - NOT FOR FURTHER DISTRIBUTION	ImmunoGen, Inc. April 4, 2023 CONFIDENTIAL INFORJ
Nov 28, 2022	97693879	Pending	ELAHERE MIRVETUXIMAB SORAVTANSINE INJECTION 100 MG SUPPORT SERVICES (IL Starburst Logo)	P Z:	901	S	7033
		THEHS-SWI.	ELAHERE MIRVETUXIMAB SORAYTANSINE INJECTION 100 MG SUPPORT SERVICES (& Starburst Logo)	MPR	001	GB	7033
		TWK-SHELL	ELAHERE MIRVETUXIMAB SORAYTANSINE INJECTION 100 MG SUPPORT SERVICES (B Starburst Logo)	<i>M</i> ₽R	901	БЖ	7033
Nov 28, 2022	97693878	Pending	ELAHERE SUPPORT SERVICES (6 Starburst Logo)	PRI	001	ß	7007

TRADEMARK
RECORDED: 04/06/2023 REEL: 008035 FRAME: 0727